$ULBI

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.

Original reporting
Published Aug 8, 2026, 2:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 2:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ultralife (ULBI) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ULBIBullishMed
01

Why it matters

Traders can update expectations for near-term revenue capture (communications order pull-through), gross margin sustainability (tariff refund and mix), and shipment cadence for conformal wearable batteries and water-based drone platforms.

02

Market read

Record backlog and a large gross margin improvement are the headline fundamentals, with additional timing-based revenue and shipment expectations that can drive revisions to near-term estimates.

03

What to watch

Battery and Energy revenue declined due to oil and gas weakness; margin gains may depend on one-time tariff refund and favorable mix rather than fully recurring improvements.

Relevance 8/10Novelty 7/10Timing: pre-market today, following the Q2 2026 earnings call transcript

Background

Ultralife’s Q2 2026 earnings call covers segment performance (Battery and Energy, Communications Systems), backlog trends, margin drivers, and updates on product and manufacturing initiatives.

Company-level read

Ticker impact

$ULBIBullishMedium confidence
Context

Ultralife reported Q2 2026 revenue of $47.9M, record $117.5M backlog, and gross margin expansion to 28.9% on the call.

Expected impact

Bias toward upside if investors focus on backlog growth and margin trajectory; downside risk if communications revenue timing or defense/drone demand assumptions disappoint.

Evidence & confidence

The article provides multiple concrete operating metrics (revenue, EPS, backlog, gross margin, EBITDA) plus forward-looking shipment and demand expectations, which can re-rate near-term fundamentals.

Market effects

Signals improving profitability in battery and defense electronics supply chains, potentially supporting sentiment for niche defense battery suppliers.

Limited direct regional read-through; references to Raynham facility and domestic manufacturing tax credit are US-focused.

Geopolitical oil and gas sales headwind is noted, but the main incremental narrative is defense and medical wearables demand.

Counterpoint

Communications Systems growth is attributed to order timing, so near-term revenue may be volatile even with a record backlog.

Key entities

  • Ultralife Corporation

    Reported Q2 2026 results and provided backlog, margin, and forward-looking shipment and demand commentary.

  • Michael Manna

    CEO who discussed backlog pull-through and strategic execution priorities.

  • Philip A. Fain

    CFO who addressed equipment reliability and margin drivers.

Related articles

$ENSHighAI 9/10

EnerSys to Acquire Ultralife for $16 Per Share in Cash

EnerSys (ENS) agreed to acquire Ultralife for $16 per share in cash. The deal, subject to regulatory approvals, includes support from shareholders holding 40.3% of Ultralife's shares. The tender offer is expected to start within 10 business days and may close by April 27, 2027, with possible extensions.

$ENSHighAI 9/10

EnerSys to acquire Ultralife for $320 million in cash

EnerSys (ENS) agreed to acquire Ultralife (ULBI) for $320 million in cash, including debt. Ultralife shareholders will receive $16.00 per share, a 166% premium over Monday's closing price. The deal, approved by both boards, is expected to close in Q1 2027. EnerSys will finance the acquisition with available cash. Both companies' CEOs cited strategic benefits and value creation.

$ULBIMed

Ultralife Corporation Reports Second Quarter Results

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil